Japan’s Universal Artificial Blood

 

Purple Promise: the Global Race to End Transfusion Shortages

Scientific American–Style Feature

Biomedical Engineering • Transfusion Medicine

Researchers at Nara Medical University have engineered hemoglobin vesicles that work for all blood types and last for years. As clinical trials advance, parallel efforts in the U.S. and U.K. are converging on a long-elusive goal: a shelf-stable substitute for donated blood. This could revolutionize emergency room and battlefield emergency care.

 

By Stephen “Pseudo Publius” | April 2026 

 

Bottom Line Up Front (BLUF): Researchers at Nara Medical University in Japan are conducting a Phase Ib clinical trial of “Deoxy-HbV”—hemoglobin vesicles that function as universal, pathogen-free, blood-type-independent artificial red blood cells storable at room temperature for up to two years. The product, developed over two decades by Professor Hiromi Sakai’s team, builds on a successful 2022 Phase I first-in-human trial. The ongoing Phase Ib study, which began recruiting in May 2025, is administering doses up to 400 mL to 16 healthy volunteers with a planned completion date of June 2026. In parallel, the U.K.’s RESTORE trial is testing stem-cell-derived red blood cells, while the U.S. military’s $46.4 million DARPA-funded FSHARP program is developing ErythroMer, a freeze-dried synthetic red blood cell designed for battlefield use. If Japan’s trials succeed, clinical deployment could begin as early as 2030—a milestone that would constitute the first broadly usable artificial blood product in medical history. The global stakes are immense: over 100 million units of blood go unmet annually in low- and middle-income countries, and hemorrhage kills an estimated 1.9 million people worldwide each year.

A Century-Long Quest Enters a New Phase

The bottle is conspicuously purple. Labeled “Deoxy-HbV” with a “For Display Only” sticker from Nara Medical University, it looks more like a chemistry demonstration than a medical breakthrough. But the unassuming vial represents the leading edge of a research program that has eluded scientists for more than a century: creating a safe, effective, universally compatible substitute for human blood.

The purple color is itself instructive. Hemoglobin, the oxygen-carrying protein in red blood cells, appears deep violet in its deoxygenated state—the form in which it is stored for maximum shelf stability. Upon infusion and exposure to oxygen in the lungs, it would shift toward the familiar crimson. The color difference, in other words, is a feature, not a defect—a visual signature of the deliberate biochemistry that makes long-term storage possible.

Professor Hiromi Sakai of Nara Medical University’s Department of Chemistry has spent more than 20 years refining the technology behind these hemoglobin vesicles (HbVs). Her team extracts hemoglobin from expired donor blood—units past the 21-day clinical use window that would otherwise be discarded—purifies it, and encapsulates the concentrated protein within PEGylated phospholipid vesicles (liposomes) roughly 225–285 nanometers in diameter. The resulting particles mimic the oxygen-carrying function of natural red blood cells while eliminating the characteristics that make conventional transfusion medicine so logistically demanding: blood-type antigens, pathogen risk, and perishability.

The Engineering of a Synthetic Red Blood Cell

The technical architecture of HbVs reflects decades of iterative refinement driven by the failures of earlier hemoglobin-based oxygen carriers (HBOCs). First-generation acellular HBOCs—chemically modified hemoglobin solutions without any encapsulating membrane—proved dangerous. A 2008 meta-analysis published in the Journal of the American Medical Association found that these products carried statistically elevated risks of myocardial infarction and death. The mechanisms were well understood: free hemoglobin molecules, small enough to escape blood vessels, scavenged nitric oxide (a critical vasodilator), triggering vasoconstriction, hypertension, and oxidative tissue damage.

Sakai’s approach addresses these problems structurally. By wrapping hemoglobin inside a lipid bilayer membrane, HbVs keep the protein compartmentalized—just as natural red blood cells do—preventing extravasation and nitric oxide scavenging. The PEG (polyethylene glycol) coating on the vesicle surface enhances biocompatibility and extends circulation time. The lipid composition—1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), cholesterol, DHSG, and DSPE-PEG—has been optimized through extensive preclinical testing to balance membrane stability, oxygen permeability, and immunological inertness.

A key manufacturing innovation was the development of a rotation-revolution mixer for hemoglobin encapsulation, which dramatically improved production yield and enabled the scale-up from bench quantities to clinical-grade lots produced at Nara Medical University Hospital’s Cell Processing Center. The hemoglobin source material undergoes nucleic acid amplification testing (NAT), pasteurization, nanofiltration, and ultrafiltration, producing a pathogen-free product. After encapsulation, the suspension is completely deoxygenated and sealed in aluminum-laminated bags with oxygen absorbers for long-term storage.

“The product solved four problems simultaneously: infection risk, blood-type mismatch, immunological response, and insufficient shelf life for stockpiling in emergencies.”
—Nara Medical University, HbV research program description

From First-in-Human to Phase Ib: The Clinical Evidence

The scientific trajectory of HbV development follows a methodical progression. After completing GLP-compliant nonclinical safety evaluations in rodents and dogs by 2019—conducted under guidance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)—Sakai’s team initiated small-scale GMP production in 2020 and launched a Phase I first-in-human trial (HbV-101). Published in Blood Advances in November 2022, the study enrolled 11 healthy male volunteers in three dose-escalation cohorts receiving 10, 50, and 100 mL of HbV suspension, administered intravenously at rates of 1 to 2.5 mL per minute. The primary finding: the vesicles were safe and well-tolerated at all tested doses, with no serious adverse events reported. Pharmacokinetic data confirmed that HbVs remained detectable in the plasma fraction after administration, and no significant complement activation or anti-PEG antibody responses were observed in the highest-dose cohort.

Building on these results, a Phase Ib study protocol was published in BMJ Open in January 2026. This single-center, open-label, dose-escalation trial at Nara Medical University plans to enroll 16 healthy volunteers divided into four cohorts receiving 100 mL (cohorts 1 and 2), 200 mL (cohort 3), and 400 mL (cohort 4), with infusion rates escalating to a maximum of 5.0 mL per minute. The primary endpoints are safety—assessed as the incidence of adverse events within 14 days and clinically significant changes from baseline within 72 hours—and pharmacokinetics, including maximum blood concentration, AUC, and elimination half-life. Recruitment for the first cohort began in May 2025, with the final cohort planned for May–June 2026. The study is funded by the Japan Agency for Medical Research and Development (AMED) and a Nara Medical University Clinical Research Grant.

Separate preclinical research has explored additional therapeutic applications beyond oxygen transport. The Sakai laboratory has demonstrated that carbonyl-hemoglobin vesicles (CO-HbV) can serve as carbon monoxide carriers, while methemoglobin vesicles (metHbV) function as antidotes for certain poisonous substances. Animal studies using CO-HbV showed no marked hippocampal damage or behavioral abnormalities, even at doses up to 32 mL/kg. All three variants—deoxy-HbV, CO-HbV, and metHbV—can be stored for years at room temperature.

Three Approaches, One Goal: Competing Artificial Blood Programs

Japan — Hemoglobin Vesicles (HbV): Lipid-encapsulated human hemoglobin from expired blood. Phase Ib trial underway at Nara Medical University. Universal blood type, two-year room-temperature shelf life. Target clinical deployment: 2030.

United States — ErythroMer (KaloCyte/DARPA FSHARP): Synthetic nanoparticle mimicking red blood cells, using recycled human hemoglobin wrapped in an engineered membrane. Designed to be freeze-dried and reconstituted with saline. $46.4 million DARPA funding. Animal trials successful; human trials targeted within two years (as of mid-2025).

United Kingdom — RESTORE Trial (NHS Blood and Transplant/University of Bristol): Laboratory-grown red blood cells derived from donor stem cells. First-in-world transfusion of lab-grown RBCs into humans in November 2022. Crossover trial comparing longevity of lab-grown versus conventional donor cells. Results expected late 2025.

The American Parallel: ErythroMer and the DARPA Wager

While Sakai’s team pursues a liposome-encapsulation strategy, researchers at the University of Maryland School of Medicine are taking a related but distinct approach. Allan Doctor, a physician-scientist and director of the Center for Blood Oxygen Transport and Hemostasis, co-founded KaloCyte in 2016 to develop ErythroMer—a synthetic nanoparticle that mimics the oxygen-transport functions of red blood cells. Like HbVs, ErythroMer uses recycled hemoglobin from expired donor blood enclosed in a lipid membrane. But ErythroMer is engineered to be freeze-dried into a powder that can be reconstituted with saline at the point of care—a critical feature for military and pre-hospital applications where refrigeration is unavailable.

In January 2023, DARPA awarded a $46.4 million, four-year grant to a University of Maryland–led consortium under the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program. The project aims to develop a complete shelf-stable whole blood equivalent that includes ErythroMer as its oxygen-carrying component, alongside synthetic platelets developed by Anirban Sen Gupta of Case Western Reserve University (under development by Haima Therapeutics) and a freeze-dried plasma product from Teleflex. The overarching goal is a field-deployable product that military medics can administer within 30 minutes of injury.

Animal trials have been encouraging. KaloCyte researchers have successfully replaced up to 90 percent of blood volume in rabbits with ErythroMer and observed stable vital signs. Doctor has publicly stated that he hopes to begin human trials within approximately two years, with commercial availability potentially five to eight years out if FDA approval proceeds smoothly.

The military urgency driving the FSHARP program is stark. Hemorrhage remains the leading cause of preventable death on the battlefield, and roughly 30,000 Americans each year bleed to death before reaching a hospital. Ambulances, helicopters, and field medics generally cannot carry blood products because of the cold-chain requirements that make conventional packed red blood cells viable for only 30 to 42 days under refrigeration.

The British Approach: Growing Blood from Stem Cells

The RESTORE trial, led by NHS Blood and Transplant in collaboration with the University of Bristol, University of Cambridge, and Guy’s and St Thomas’ NHS Foundation Trust, represents a fundamentally different strategy. Rather than engineering a synthetic oxygen carrier, the British program grows actual red blood cells from donor stem cells in the laboratory. In November 2022, the trial achieved a landmark: the first-ever transfusion of lab-grown red blood cells into a human recipient. At least two participants received mini-doses of the cultured cells in a crossover design comparing the survival and circulation time of lab-grown versus conventionally donated cells from the same donor.

The hypothesis is that freshly manufactured red blood cells, being uniformly young, will persist longer in the recipient’s circulation than standard donor blood, which contains cells of mixed ages—many of which are already near the end of their approximately 120-day lifespan. If confirmed, this could reduce the frequency of transfusions required by patients with chronic conditions such as sickle cell disease and thalassemia. Results from RESTORE are expected by late 2025, though the investigators have been clear that routine clinical use of lab-grown blood, if feasible, remains years away.

The Checkered History of Blood Substitutes

The scientific enthusiasm surrounding these programs must be tempered by the sobering history of hemoglobin-based oxygen carriers. The pursuit of artificial blood has been marked by repeated failure and, in some cases, patient harm.

Baxter Corporation’s HemAssist (diaspirin cross-linked hemoglobin) was abandoned after a U.S. trial was halted when the first 100 patients showed significantly increased mortality compared to those receiving conventional blood products. Northfield Laboratories’ PolyHeme progressed through a controversial Phase III trial but demonstrated a non-significant trend toward increased mortality and only modest reduction in subsequent blood needs. Biopure Corporation, developer of Hemopure (HBOC-201, a glutaraldehyde-polymerized bovine hemoglobin), failed to obtain FDA approval and filed for bankruptcy in 2009; its assets passed through two successive owners before landing with HbO2 Therapeutics, which currently provides Hemopure under the FDA’s Expanded Access Program for life-threatening cases where no other options exist. Hemopure remains approved for clinical use in South Africa (since 2001) and Russia (since 2010), making it the only HBOC product with any regulatory authorization for human use.

The common thread in these failures was the toxicity of unencapsulated hemoglobin. Free hemoglobin molecules scavenge nitric oxide, causing vasoconstriction and hypertension; they are small enough to extravasate into tissue, causing oxidative damage; and they exert osmotic pressures that can lead to volume overload. These adverse effects collectively drove a 2008 JAMA meta-analysis to conclude that acellular HBOCs carried higher risks of myocardial infarction and death.

The newer generation of encapsulated products—HbVs, ErythroMer, and related approaches—are explicitly designed to avoid these failure modes. By containing hemoglobin within a membrane that mimics the structure (if not the biology) of a red blood cell, they prevent the molecular-level interactions that proved so destructive. Whether this design principle translates into clinical safety at therapeutic doses in patients with acute hemorrhage—rather than healthy volunteers—remains the central unanswered question.

The Global Blood Crisis: Why This Matters

The clinical urgency driving artificial blood research extends far beyond the laboratory. The World Health Organization reports that approximately 118.5 million blood donations are collected annually worldwide, but 40 percent of that volume comes from high-income countries that represent just 16 percent of the global population. A 2019 modeling study published in The Lancet Haematology found that 119 of 195 countries lack sufficient blood to meet hospital needs, with a global deficit exceeding 100 million units per year. Every country in sub-Saharan Africa, South Asia, and Oceania (excluding Australasia) falls short.

The consequences are measured in deaths. Global hemorrhage-related mortality is estimated at 1.9 million per year. A quarter of maternal in-hospital deaths from peripartum hemorrhage in sub-Saharan Africa have been attributed to blood shortages. The FEAST trial, conducted in Uganda, Kenya, and Tanzania, found that more than half of children presenting with febrile illness and severe anemia died when transfusion was delayed more than eight hours, compared to a four percent mortality rate with timely transfusion.

Japan faces its own demographic version of this crisis. With nearly 30 percent of its population over age 65 and a collapsed replacement birth rate, the country confronts a structural mismatch: the population most likely to need transfusions is growing, while the population able to donate is shrinking. This demographic pressure—shared in varying degrees by South Korea, Taiwan, and much of Europe—gives Japan both the incentive and the institutional capacity to pursue artificial blood with unusual determination.

A universal, shelf-stable blood substitute could transform not only emergency medicine in resource-poor settings but also military trauma care, disaster response, and the management of patients with rare blood types or religious objections to conventional transfusion. The economic implications are substantial: the artificial blood substitute market, currently valued at roughly $12 million, is projected to reach $75 million by 2035, driven by clinical research advances and growing demand.

Obstacles and Open Questions

Significant scientific and regulatory hurdles remain. The Phase Ib trial underway at Nara Medical University is testing safety in healthy volunteers—a population very different from the hemorrhagic trauma patients who would be the primary recipients in clinical practice. The jump from 400 mL doses in healthy adults to the volumes needed for resuscitation of a bleeding patient (potentially several liters) represents a formidable pharmacological and immunological challenge. Questions about repeated dosing, long-term metabolic processing of infused hemoglobin and lipid components by the reticuloendothelial system (primarily the liver and spleen), and potential complement activation at high volumes remain under investigation.

The manufacturing scalability question is equally critical. Currently, HbVs are produced at the Cell Processing Center of Nara Medical University Hospital—an academic facility, not a pharmaceutical manufacturing plant. Transitioning to industrial-scale production while maintaining the purity, sterility, and consistency required for a parenteral biological product will demand major capital investment and regulatory engagement. The source material—expired donor blood from the Japanese Red Cross—imposes its own supply constraints, albeit ones far less severe than those governing fresh blood.

ErythroMer faces analogous challenges. KaloCyte’s current shelf life for the freeze-dried product is several months, short of the two-year target needed for practical field deployment. The transition from successful rabbit models to human Phase I trials will require FDA clearance of an investigational new drug application—a process that, given the fraught regulatory history of HBOCs, is likely to receive particularly rigorous scrutiny.

The RESTORE trial, while scientifically elegant, confronts a different limitation: scale. Growing red blood cells from stem cells in sufficient quantity for routine transfusion remains prohibitively expensive and labor-intensive. The investigators have been forthright that, even if successful, lab-grown blood would initially serve only a tiny population of patients with complex transfusion needs and rare blood types.

Convergence and Outlook

What is remarkable about the current moment is the convergence of multiple credible approaches after decades of failure. Japan’s HbV program, the American military-industrial ErythroMer effort, and the British stem-cell approach are each advancing through human trials or toward them, supported by government funding, institutional infrastructure, and peer-reviewed science. This is no longer a fringe pursuit sustained by venture capital optimism; it is a mature, multi-national research program with regulatory pathways actively under negotiation.

If Sakai’s Phase Ib trial confirms safety at clinically meaningful doses and proceeds to Phase II efficacy studies, Japan could become the first country in the world to deploy a universal artificial blood product for routine clinical use—a milestone the research team has targeted for 2030. That timeline is ambitious but not implausible, given the 20-year foundation of preclinical work and the Japanese regulatory framework’s track record with translational medicine.

The purple liquid in the Nara Medical University vial is not, as viral social media posts have sometimes implied, “lab-grown blood.” It does not contain red blood cells, white blood cells, platelets, or plasma proteins. It cannot replace whole blood. What it can do—if the clinical evidence holds—is carry oxygen to tissues when natural blood is unavailable, buying time for patients who would otherwise die. In a world where 1.9 million people bleed to death each year, buying time may be the most consequential medical intervention imaginable.

Verified Sources and Formal Citations

1. Azuma H, Amano T, Kamiyama N, Takehara N, Jingu M, Takagi H, Sugita O, Kobayashi N, Kure T, Shimizu T, Ishida T, Matsumoto M, Sakai H. “First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative.” Blood Advances. 2022;6(21):5711–5715. doi:10.1182/bloodadvances.2022007977.
   https://ashpublications.org/bloodadvances/article/6/21/5711/486139/
2. Sakai H, Kure T, Taguchi K, Azuma H. “Research of storable and ready-to-use artificial red blood cells (hemoglobin vesicles) for emergency medicine and other clinical applications.” Frontiers in Medical Technology. 2022;4:1048951. doi:10.3389/fmedt.2022.1048951.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC9816666/
3. Azuma H, Kasahara M, Matsumoto M, et al. “Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan.” BMJ Open. 2026;16(1):e110183. doi:10.1136/bmjopen-2025-110183.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12829376/
4. Sakai H, Kure T, Kobayashi N, et al. “Absence of Anaphylactic Reactions to Injection of Hemoglobin Vesicles (Artificial Red Cells) to Rodents.” ACS Omega. doi:10.1021/acsomega.3c08641.
   https://pubs.acs.org/doi/10.1021/acsomega.3c08641
5. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. “Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.” JAMA. 2008;299(19):2304–2312.
   https://pubmed.ncbi.nlm.nih.gov/18443023/
6. Jahr JS, Guinn NR, Lowery DR, Shore-Lesserson L, Shander A. “Blood substitutes and oxygen therapeutics: a review.” Anesthesia & Analgesia. 2021;132(1):119–129.
   https://pubmed.ncbi.nlm.nih.gov/33105279/
7. Jahr JS. “Blood substitutes: Basic science, translational studies and clinical trials.” Frontiers in Medical Technology. 2022;4:989829.
   https://www.frontiersin.org/articles/10.3389/fmedt.2022.989829/full
8. Jahr JS, MacKinnon K, Baum VC, Alayash AI. “Hemoglobin-based oxygen carriers: Biochemical, biophysical differences, and safety.” Transfusion. 2025;65(2). doi:10.1111/trf.18126.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC11826291/
9. Elahi MF, et al. “Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?” Medicina. 2023;59(2):396.
   https://www.mdpi.com/1648-9144/59/2/396
10. Elahi MF, et al. “Hemoglobin-Based Oxygen Carriers: Selected Advances and Challenges in the Design of Safe Oxygen Therapeutics.” Medicina. 2025;61(10). PMC12525027.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12525027/
11. University of Cambridge. “First ever clinical trial underway of laboratory grown red blood cells being transfused into another person.” November 7, 2022.
    https://www.cam.ac.uk/research/news/first-ever-clinical-trial/
12. NHS Blood and Transplant. “First ever clinical trial of laboratory grown red blood cells being transfused into another person.” November 7, 2022.
    https://www.nhsbt.nhs.uk/news/first-ever-clinical-trial/
13. NHS Blood and Transplant. “The NHSBT-led RESTORE trial into growing blood featured in The New Yorker.”
    https://www.nhsbt.nhs.uk/news/the-nhsbt-led-restore-trial/
14. University of Maryland, Baltimore. “Artificial Blood One Step Closer to Reality.” February 2023.
    https://www.umaryland.edu/news/archived-news/february-2023/artificial-blood.php
15. NPR. “Scientists are developing artificial blood that could save lives in emergencies.” July 24, 2025.
    https://www.npr.org/sections/shots-health-news/2025/07/24/artificial-blood
16. CBS Baltimore. “Synthetic, shelf-stable blood developed by Maryland scientist could save lives in emergencies.” August 8, 2025.
    https://www.cbsnews.com/baltimore/news/maryland-synthetic-blood/
17. Science. “The ultimate blood substitute? The U.S. military is betting $46 million on it.” July 3, 2024.
    https://www.science.org/content/article/ultimate-blood-substitute
18. HbO2 Therapeutics. “Hemopure” product information page.
    https://www.hbo2therapeutics.com/our-product
19. ClinicalTrials.gov. “Expanded Access Study of HBOC-201 (Hemopure).” NCT01881503.
    https://clinicaltrials.gov/study/NCT01881503
20. World Health Organization. “Blood safety and availability.” Fact sheet, updated May 2025.
    https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability
21. Roberts N, James S, Delaney M, Fitzmaurice C. “The global need and availability of blood products: a modelling study.” The Lancet Haematology. 2019;6(12):e606–e615.
22. Raykar NP, Makin J, Khajanchi M, et al. “Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions.” SAGE Open Medicine. 2021;9:20503121211054995.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8591638/
23. Bloch EM, et al. “Ensuring a Safe and Sufficient Global Blood Supply.” New England Journal of Medicine. 2024. doi:10.1056/NEJMp2403596.
    https://www.nejm.org/doi/full/10.1056/NEJMp2403596
24. Japan Registry of Clinical Trials. Phase I HbV trial registration: jRCT2011200004.
    https://jrct.niph.go.jp/en-latest-detail/jRCT2011200004
25. NIHR Innovation Observatory. “Horizon Scan of the Artificial Blood Research and Funding Landscape.” September 2024.
    https://www.io.nihr.ac.uk/wp-content/uploads/2024/09/Artificial-Blood-Report.pdf
26. Newsweek. “Artificial Blood That Could Work for All Blood Types in Trials.” June 2, 2025.
    https://www.newsweek.com/artificial-blood-japan-all-blood-types-2079654
27. Nara Medical University. “Production of artificial red blood cell preparations and Phase I clinical trials.” University Journal Online. July 2024.
    https://univ-journal.net/246679/